drugset / Trial / NCT00653068

Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

NCT00653068

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This phase III trial studies the side effects of combination chemotherapy, 3-dimensional conformal radiation therapy, and an autologous peripheral blood stem cell transplant, and to see how well they work in treating young patients with atypical teratoid/rhabdoid tumor of the central nervous system. Giving high-dose chemotherapy before an autologous peripheral blood stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving colony-stimulating factors, such as G-CSF, helps stem cells move from the bone marrow to the blood so they can be collected and stored. Chemotherapy or radiation therapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy or radiation therapy.

Timeline

Start
2009-02-10
Primary completion
2016-09-27
Completion
2024-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule Intravenous
Subject Cisplatin Other / unclassified Intravenous
Subject Cyclophosphamide Other / unclassified Intravenous
Subject Etoposide Small molecule Intravenous
Subject Methotrexate Small molecule Intravenous
Subject Thiotepa Other / unclassified Intravenous
Subject Vincristine Small molecule Intravenous
Background Leucovorin Small molecule Intravenous
Background filgrastim Protein / enzyme biologic Intravenous